As we continue to push boundaries in #ADC research, we are honored to be awarded the Best Clinical Publication at this year’s World ADC Event Series in San Diego. Congratulations to the SORAYA clinical team for their research. Learn more about our efforts in cancer research: https://bit.ly/4eqSh7d
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
Oyewale Daejin Abidoye, our VP, therapeutic area head, solid tumor, explains the need to improve clinical practices for #biomarker testing in non-small cell lung cancer (#NSCLC). Health care disparities continue to exist in biomarker testing, especially for those in socially disadvantaged communities. Read his latest article to learn more. #LungCancerAwarenessMonth https://lnkd.in/gzg9uFv9
Improving clinical practices for biomarker testing is important to inform treatment approaches for patients with non-small cell lung cancer (#NSCLC), especially for those in underserved communities. Here are my thoughts on the importance of addressing this unmet need. #LungCancerAwarenessMonth #LCAM
-
Hear members of our #Veterans employee resource group discuss their connection to the #VeteransDay theme: legacy to loyalty and service. Learn more about our support for veterans and how they impact our workplace: https://bit.ly/3AFdXPf #BelongAtAbbVie [Video description: Members of the AbbVie Veterans Employee Resource Group share what living with a legacy to loyalty and service means to them.]
-
Genetic medicines have the potential to revolutionize patient care. But how do they work? Learn more in a Q&A with Clark Pan, our VP of biotherapeutics and genetic medicine technologies, and discover how we’re using #GeneticMedicine technologies and platforms to find treatments for patients: https://lnkd.in/g9pUGR7f [Image description: A series of illustrations depicting how genetic medicine works once entered in the body via a vector.]
-
ICYMI: Members of our executive leadership team discussed our Q3 2024 #FinancialResults during this week’s #earnings call. Swipe to learn more about our performance from our leaders. $ABBV [Image description: Members of AbbVie’s executive leadership team share their remarks on our Q3 2024 Financial Results, including: Robert A. Michael, Jeffrey R. Stewart, Carrie Strom, Roopal Thakkar and Scott T. Reents.]
-
The Ways We Work are the five pillars at the foundation of our culture guiding how our employees innovate and collaborate. Throughout October, employees worldwide participated in our annual Celebration of Culture, where they recognized how their individual actions enable us to make a real difference in people’s lives – while also making us a great place to work. Learn more: https://bit.ly/4hsDTOE #AbbVieLife
-
-
Wishing a sincere Shubh Deepavali to all who are celebrating the start of #Diwali, the Festival of Lights. #BelongAtAbbVie [Video description: Imagery showing Diwali celebrations including sparklers, lights and lanterns, and candles.]
-
NEWS: Today we announced a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop novel multispecific therapeutic antibodies for solid and hematologic malignancies. Learn more: https://bit.ly/4frlfVv #oncology #cancer [Video description: On-screen text reads, "Oncology News."]
-
"We delivered another quarter of strong commercial execution and significant pipeline progress. Based upon the momentum of AbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend," said Rob Michael, our CEO. Learn more about our Q3 2024 #FinancialResults: https://abbv.ie/1e204b $ABBV #earnings [Image description: Summary of AbbVie's Q3 2024 Financial Results, including Raised 2024 Adjusted Diluted EPS Guidance Range, Quarterly Dividend Growth, Adjusted R&D Investment and Net Revenues by Therapeutic Area.]
-
Today on #WorldPsoriasisDay, we are reminded that psoriatic disease not only impacts the patient, but also their loved ones, including families, partners and caregivers. Through ongoing research and dedication to immune-mediated skin diseases, like psoriasis, we strive to meet patient needs and support the community globally. IFPA's report highlights the full impact of psoriasis: https://bit.ly/4hkWKLr [Video description: Vassilis Stakias, Global TA Lead, Dermatology, Global Medical Affairs, AbbVie, says, “Everyday, we prioritize the needs of the patients living with psoriatic disease, so they can feel free in their own skin. This World Psoriasis Day, we also support and recognize how psoriatic disease can impact those beyond the patient in solidarity with the dermatology community.”]
Affiliated pages
Similar pages
Stock
ABBV
NYSE
20 minutes delay
$171.09
-3.34 (-1.915%)
- Open
- 176.01
- Low
- 171.03
- High
- 176.63
Data from Refinitiv
See more info on